文献

J-GLOBAL ID：201702280417643725   整理番号：17A0317169

癌における薬理ゲノム学的相互作用の景観【Powered by NICT】

A Landscape of Pharmacogenomic Interactions in Cancer

著者 (56件)： Iorio Francesco (European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Iorio Francesco (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Knijnenburg Theo A. (Institute for Systems Biology, Seattle, WA 98109, USA) ,  Knijnenburg Theo A. (Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands) ,  Vis Daniel J. (Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands) ,  Bignell Graham R. (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Menden Michael P. (European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Menden Michael P. (Faculty of Medicine, Joint Research Centre for Computational Biomedicine, RWTH Aachen University, Aachen 52057, Germany) ,  Schubert Michael (European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Aben Nanne (Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands) ,  Aben Nanne (Department of EEMCS, Delft University of Technology, Delft 2628 CD, the Netherlands) ,  Goncalves Emanuel (European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Barthorpe Syd (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Lightfoot Howard (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Cokelaer Thomas (European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Cokelaer Thomas (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Greninger Patricia (Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA) ,  van Dyk Ewald (Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands) ,  Chang Han (Genetically Defined Diseases and Genomics, Bristol-Myers Squibb Research and Development, Hopewell, NJ 08534, USA) ,  de Silva Heshani (Genetically Defined Diseases and Genomics, Bristol-Myers Squibb Research and Development, Hopewell, NJ 08534, USA) ,  Heyn Holger (Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet 08908, Barcelona, Catalonia, Spain) ,  Deng Xianming (Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA) ,  Deng Xianming (Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA) ,  Egan Regina K. (Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA) ,  Liu Qingsong (Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA) ,  Liu Qingsong (Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA) ,  Mironenko Tatiana (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Mitropoulos Xeni (Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA) ,  Richardson Laura (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Wang Jinhua (Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA) ,  Wang Jinhua (Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA) ,  Zhang Tinghu (Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA) ,  Zhang Tinghu (Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA) ,  Moran Sebastian (Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet 08908, Barcelona, Catalonia, Spain) ,  Sayols Sergi (Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet 08908, Barcelona, Catalonia, Spain) ,  Soleimani Maryam (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Tamborero David (Research Program on Biomedical Informatics, IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona 08003, Spain) ,  Lopez-Bigas Nuria (Research Program on Biomedical Informatics, IMIM Hospital del Mar Medical Research Institute and Universitat Pompeu Fabra, Barcelona 08003, Spain) ,  Lopez-Bigas Nuria (Institucio Catalana de Recerca i Estudis Avancats (ICREA), 08010 Barcelona, Catalonia, Spain) ,  Ross-Macdonald Petra (Genetically Defined Diseases and Genomics, Bristol-Myers Squibb Research and Development, Hopewell, NJ 08534, USA) ,  Esteller Manel (Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet 08908, Barcelona, Catalonia, Spain) ,  Esteller Manel (Institucio Catalana de Recerca i Estudis Avancats (ICREA), 08010 Barcelona, Catalonia, Spain) ,  Esteller Manel (Department of Physiological Sciences II of the School of Medicine, University of Barcelona, L’Hospitalet 08908, Barcelona, Catalonia, Spain) ,  Gray Nathanael S. (Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA) ,  Gray Nathanael S. (Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA) ,  Haber Daniel A. (Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA) ,  Haber Daniel A. (Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA) ,  Stratton Michael R. (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Benes Cyril H. (Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA) ,  Wessels Lodewyk F.A. (Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands) ,  Wessels Lodewyk F.A. (Department of EEMCS, Delft University of Technology, Delft 2628 CD, the Netherlands) ,  Wessels Lodewyk F.A. (Cancer Genomics Netherlands, Uppsalalaan 8, Utrecht 3584CT, the Netherlands) ,  Saez-Rodriguez Julio (European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Saez-Rodriguez Julio (Faculty of Medicine, Joint Research Centre for Computational Biomedicine, RWTH Aachen University, Aachen 52057, Germany) ,  McDermott Ultan (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK) ,  Garnett Mathew J. (Wellcome Trust Sanger Institute, Wellcome Genome Campus, Cambridge CB10 1SA, UK)
資料名： Cell (Cambridge, Mass.)  (Cell (Cambridge, Mass.))
巻： 166  号： 3  ページ： 740-754  発行年： 2016年 
JST資料番号： A0707B  ISSN： 0092-8674  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： 癌ゲノムの系統的研究は,癌の分子的性質への前例のない洞察を提供した。臨床における治療法の開発および応用をガイドするためにこの情報を使用することは,挑戦的である。ここでは,29種類の組織(体細胞変異,コピー数変化,DNAメチル化および遺伝子発現を統合した)から11,289腫瘍で同定された癌駆動変化は1,001分子アノテートされたヒト癌細胞株上にマッピングし,265剤に対する感受性と相関させることができるかを報告した。細胞株を忠実に腫瘍内に同定される発癌性変化を再現する,これらの多くは薬剤感受性/耐性と関連があることを見出す,薬物応答の仲介における組織系統の重要性を強調することを見出した。論理ベースモデリングは,薬物に鋭敏にする変化の組合せを明らかにする,機械学習は,薬物反応を予測する異なるデータタイプの相対的重要性を明らかにした。解析とデータセットは細胞表現型と遺伝子型を連結し,選択した腫瘍亜集団に対する治療オプションを識別するために豊富な資源である。Copyright 2017 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【Powered by NICT】

シソーラス用語： 腫瘍 ,  遺伝子型 ,  コピー数 ,  機械学習 ,  *ゲノム ,  発癌性 ,  データ型 ,  薬剤感受性 ,  表現型
準シソーラス用語： 薬物反応 ,  細胞株 ,  腫瘍細胞株 ,  DNAメチル化 ,  体細胞突然変異 ,  *ゲノム薬理学 , 【Automatic Indexing@JST】

分類 (1件)： 細胞生理一般  (EF02010S)

タイトルに関連する用語 (4件)： 癌 ,  薬理ゲノム学 ,  相互作用 ,  景観